Direct Helpers Research Center

1. Takeda Pharmaceuticals U.S.A., Inc. $3,638,962 239 payments
2. Amgen Inc. $2,595,235 32 payments
3. Incyte Corporation $1,157,607 940 payments
4. Taro Pharmaceuticals USA, Inc. $970,124 142 payments
5. Exeltis, USA Inc. $930,645 28 payments
6. Otsuka Pharmaceutical Development & Commercialization, Inc. $670,815 12 payments
7. LEO Pharma AS $568,268 83 payments
8. Dr.Reddy's Laboratories,Inc. $550,333 124 payments
9. Chiesi USA, Inc. $488,347 164 payments
10. Bausch Health US, LLC $445,756 13 payments

1. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment $1,691,526 66 payments
2. LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women $930,645 28 payments
3. AMG 451 DDI/Atopic Dermatitis $780,836 3 payments
4. Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting of A 12-Week Double-Blind, Placebo-Controlled Part (Part A) to Evaluate Efficacy and Safety Followed By A 36-Week Double-Blind Extension Part (Part B) to Document Long-Term Safety Up to Week 48 $653,363 114 payments
5. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $457,183 26 payments
6. A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) $445,756 13 payments
7. A Phase 0 Study to Assess Sleep Using Emerald Touchless Sensor in Healthy Subjects and Subjects with Moderate-to-Severe Atopic Dermatitis $419,277 1 payment
8. TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $413,737 13 payments
9. A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 $364,689 17 payments
10. The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. $361,604 193 payments

1. Professional salary support $220,200 8 payments
2. Other $8,000 2 payments
3. Overhead $4,250 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.